Over at In the Pipeline, Derek Lowe wonders what compounds might make good metabolic disease targets, harkening back to one put out there in 2002 by a company called Sumitomo Pharmaceuticals. He sees promise in CAMKK2, in that it's more upstream and involved in numerous pathways for regulation of appetite and glucose levels, including ghrelin, AMPK, and NPY. "Given the number of companies interested in this area, and the number with kinase expertise, someone's going to be able to take a good swing at this one," he says.
Taming Metabolic Disease
Jul 15, 2008